title: alpha-Interferon treatment of chronic hepatitis C: a controlled, multicentre, prospective study.
abstract: This prospective, controlled study was designed in order to evaluate the response rate to alpha-interferon (IFN) versus no treatment in 63 patients affected by chronic hepatitis C. Fifty-two patients were randomly chosen to receive no treatment of IFN alfa-2b (6 MU 3 times weekly for the first month and 3 MU for the next 11 months). Eleven additional patients were crossed to active treatment after a 1-year control period without any change of serum pattern and were therefore enrolled both as controls and cases. Four patients had to be withdrawn from the active treatment for adverse effects. Sixteen out of the remaining 23 had normal alanine aminotransferase (ALT) values at the end of the treatment, and 14 were still normal 12 months later. A liver biopsy, taken 6 months after the end of the treatment, showed improvement in 12 patients and normalization in 1. Only 1 out of the 25 controls had transaminase normalization and 5 a decrease. One of them showed also a histological improvement. Eight of the 11 case/control patients showed ALT normalization after IFN administration, 5 of them histological improvement and 2 liver normalization. Hepatitis C virus (HCV) RNA became negative in 13 of 17 cases in whom the assay was carried out. Therefore this study confirms that the longterm administration of alpha-IFN induced a prolonged remission of disease activity in over 50% of the patients and the clearance of HCV RNA in the majority of the responders.
authors.affiliation: Istituto di Clinica Medica, Università di Verona, Italia.
authors.forename: G
authors.initials: G
authors.lastname: Angelini
authors.forename: D
authors.initials: D
authors.lastname: Sgarbi
authors.forename: R
authors.initials: R
authors.lastname: Colombari
authors.forename: A
authors.initials: A
authors.lastname: Bezzi
authors.forename: A
authors.initials: A
authors.lastname: Castagnini
authors.forename: F
authors.initials: F
authors.lastname: de Berardinis
authors.forename: A
authors.initials: A
authors.lastname: Conti
authors.forename: D
authors.initials: D
authors.lastname: di Piramo
authors.forename: L
authors.initials: L
authors.lastname: Dolci
authors.forename: G
authors.initials: G
authors.lastname: Falezza
mesh_terms: D000328:Adult; D000410:Alanine Transaminase / Q000097:blood; D018592:Cross-Over Studies; D004334:Drug Administration Schedule; D005260:Female; D006526:Hepatitis C / Q000175:diagnosis / Q000628:therapy*; D006521:Hepatitis, Chronic / Q000175:diagnosis / Q000628:therapy* / Q000821:virology; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000008:administration & dosage / Q000627:therapeutic use*; D008297:Male; D011446:Prospective Studies; D012367:RNA, Viral / Q000097:blood; D011994:Recombinant Proteins; D013997:Time Factors
chemical_list: D000077190:Interferon alpha-2; D016898:Interferon-alpha; D012367:RNA, Viral; D011994:Recombinant Proteins; D000410:Alanine Transaminase